Review Article: Osteoporosis - an update

References

• World Congress on Osteoporosis. Consensus Committee, Amsterdam 1996, in press
   Google Scholar
• WHO Study Group. Assessment of fracture risk and its application to screening to postmenopausal osteoporosis. WHO Technical Report Series 843, 1994
   Google Scholar
• Lindsay R. The burden of osteoporosis costs. Am J Med 1995; 98: 9–11
   PubMed Web of Science ®Google Scholar
• Cooper C., Campion G, Melton L J, III. Hip fractures in the elderly: A world-wide projection. Osteo Int 1992; 2: 285–9
   PubMed Web of Science ®Google Scholar
• Lauritzen J B, Schwarz P, Lund B, McNair P, Transbol I. Changing incidence and residual lifetime risk of common osteoporosis related fractures. Hvidovre Osteoporosis Study Osteoporosis Int 1993; 3: 127–32
   Google Scholar
• Naessen T, Parker R, Persson I, Zack M, Amadi H-O. Time trends in incidence rates of first hip fracture in the Uppsala health care region, Sweden, 1965–1983. Am J Epidemiol 1987; 130: 279–87
   Google Scholar
• Melton L J, O'Fallon W M, Riggs B L. Secular trends in the incidence of hip fractures. Calcif Tissue Int 1987; 41: 57–64
   PubMed Web of Science ®Google Scholar
• Johnell O, Gullberg B, Allander A, Kanis J A. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis Int 1992; 2: 298–302
   PubMed Web of Science ®Google Scholar
• Riggs B L, Melton L J. Age related incidence of osteoporotic fractures. New Engl J Med 1986; 314: 1676–86
   PubMed Web of Science ®Google Scholar
• Holbrook T L, Grazier K, Kelsey J L, Stauffer R N. The frequency and occurrence, impact and cost of selected musco-loskeletal conditions in the United States. American Academy of Orthopedic Surgeons, Chicago 1984
   Google Scholar
• Schtltte H E. Social and economic impact of osteoporosis. A review of the literature. Eur J Radiol 1995; 20: 165–9
   Google Scholar
• Sernbo J, Johnell O. Consequences of a hip fracture: a prospective study of 1 year. Osteoporosis Int 1993; 3: 148–53
   PubMed Web of Science ®Google Scholar
• Lindsay R. The menopause and osteoporosis. Obstet Gynecol 1996; 87: 16S–19S, suppl, 2
   PubMedGoogle Scholar
• Bengner U. Age related fractures. Medical dissertation. Lund 1987
   Google Scholar
• Johnell O. Effect of oestrogen treatment on incidence of fragility fractures. Acta Orthoped Scand 1995
   Google Scholar
• Flicker L, Hopper J L, Rodgers L, Kaymakei B, Green R M, Wark J D. Bone density determinants in elderly women: a twin study. J Bone Miner Res 1995; 10: 1607–13
   Web of Science ®Google Scholar
• Gueguen R, Jouanny P, Guillemin F, Kuntx C., Pourel J. Segregation analysis and variance components analysis of bone mineral density in healthy families. J Bone Miner Res 1995; 10: 1027–2022
   Google Scholar
• Howard G, Nguyen T, Morrison N, Watanabe T, et al. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 1995; 80: 2800–5
   PubMed Web of Science ®Google Scholar
• Barger-Luz M J, Heaney-R P, Hayes J, DeLuca H F, Johnson M L, Gong G. Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. Calcif Tissue Int 1995; 57: 161–2
   Google Scholar
• Bedalov A, Salvatori R, Dodig M, Kronenberg M S, et al. Regulation of COLT Al expression in type I collagen producing tissues: identification of a 49 base pair region which is required for transgene expression in bone of transgenic mice. J Bone Miner Res 1995; 10: 1443–51
   PubMed Web of Science ®Google Scholar
• Sano M, Inoue S, Hosoi T, Ouchi Y, et al. Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 1995; 217: 378–83
   PubMed Web of Science ®Google Scholar
• Hogasen A KM, Nordsletten L, Aasen A O, Falch J A. There is no difference in spontaneous and 17–6-estradiol-induced interleukin-1-B release by peripheral blood mononuclear cells from non osteoporotic women with different rates of early postmenopausal bone loss. J Clin Endocrinol Metab 1995; 80: 2480–4
   Google Scholar
• Kimble R B, Matayoshi A B, Vannice J L, Kung V T, Williams C., Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 1995; 136: 3054–61
   PubMed Web of Science ®Google Scholar
• Gunnes M., Lehmann E H., Cecor A S. Dietary calcium saturated fat. fiber and vitamin C as predictors of forearm co-tical arid trabecular bone mineral density in healthy children and adolescents. Acta Paediatr 1995; 84: 388–92
   PubMed Web of Science ®Google Scholar
• Prior J C., Vigna Y M, Schechter M T., Burgess A E. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990; 323: 1221–7
   PubMed Web of Science ®Google Scholar
• Hergenroeder A C. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995; 126: 683–9
   PubMed Web of Science ®Google Scholar
• Garnero P., Sornay-Rendu E., Delmas P D., Hop E. Decreased bone turnover in oral contraceptive users. Bone 1995; 16: 499–503
   PubMed Web of Science ®Google Scholar
• Bonjour I P, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73: 555–63
   PubMed Web of Science ®Google Scholar
• Gilsanz V, et al. Peak trabecular vertebral density: a comparison of adolescent girls and adult females. Calcif Tissue Int 1988; 43: 260–2
   PubMed Web of Science ®Google Scholar
• Stevenson J C., Lees B, Devenport M., Cust M P., Ganger K F. Determinants of bone density in normal women: risk factors for future osteoporosis. Br Med J 1989; 298: 924–8
   PubMed Web of Science ®Google Scholar
• Tcitelbaum S L., Cao X., Mimura H., Chiba M, Ross P F. Cellular and molecular mechanisms of bone resorption. Miner Elecytrolyte Metab 1995; 21: 193–6
   Google Scholar
• Buckwaher J A., Glimcher M J., Cooper R R., Recker R. Bone biology. Part I + Part II. J Bone Joint Surg 1995; 77A: 1256–89
   Google Scholar
• Home W C. Toward a more complete molecular description of the osteoclast. Bone 1995; 17: 107–9
   Google Scholar
• Mundy G R. Local control of bone formation by osteoblasts. Clin Orthop 1995; 313: 19–26
   PubMedGoogle Scholar
• Menkès C-J. Metabolic bone disease. Curr Opin Rheumatol 1995; 7: 235–6
   Google Scholar
• Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 1994; 55: 82–6
   PubMed Web of Science ®Google Scholar
• Overgaard K., Lindsay R., Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17: 680–5
   Web of Science ®Google Scholar
• Juppner H. Functional properties of the PTH/PTHrP receptor. Bone 1995; 17: 39–42
   Google Scholar
• Cate J C., Papadea C. Parathyroid hormone. Part I + II. Measurement and clinical use. Lab Med 1995; 26: 599–602
   Google Scholar
• Arner E C., Tortorella M D. Signal transduction through chondrocyte integrin receptors induces matrix metalloprot-einase svnthesis and svnergizes with interleukin-1. Arthritis Rheum 1995; 38: 1304–14
   PubMedGoogle Scholar
• Manolagas S C. Role of evkotines in bone resorption. Bone 1995; 17: 6.3–7S
   Google Scholar
• Bismar H, Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80: 3351–5
   PubMed Web of Science ®Google Scholar
• Mundy GR., Boyce B., Hughes D, Wright K, et al. The effects of cytokines and growth factors on osteoblastic cells. Bone 1995; 17: 71–5S
   Google Scholar
• Levitt Katz L E., Rosenfeld R G., Cohen S P. Clinical significance of insulin-like growth factor binding proteins (ICJFBPS). Endocrinologist 1995; 5: 36–43
   Google Scholar
• Rosen C J., Donahue L R. Insulinlike growth factors: potential therapeutic options for osteoporosis. Trends Endocrinol Metab 1995; 6: 235–41
   Google Scholar
• Kanatani M, Sugimoto T., Kaji H., Kano J., Chihara K. Effects of 22-oxacalcitriol on bone metabolism in vitro: comparison with caicitriol. Effects of 22-oxacalcitriol on osteo-clast-like cell formation and bone-resorbing activity. Eur J Endocrinol 1995; 133: 618–25
   Google Scholar
• Ooms M E., Roos J C., Bezemer P H., van der Vijgh W JF, et al. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995; 80: 1052–8
   PubMed Web of Science ®Google Scholar
• Labram E K, Wilkin T J. Growth hormone deficiency in adults and its response to growth hormone replacement. Q J Med 1995; 88: 391–9
   Google Scholar
• Delmas P-D. The new definition of osteoporosis: implications for diagnosis and treatment. Menopause. European Consensus Development, M H Birkhauser, H Rozen-Baum. Montreux, Switzerland 1996, ISBN 2-86911-422-2
   Google Scholar
• Hassager C., Christiansen C. Measurements of bone mineral density. Calcif Tissue Int 1995; 57: 1–5
   PubMedGoogle Scholar
• Cheung C K, Panesar N S, Haines C., Masarei J., Swamina-Than R. Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 1995; 41: 679–86
   PubMed Web of Science ®Google Scholar
• Akesson K, Vergnaud Ph., Delmas P D., Obrant K J. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone 1995; 16: 427–30
   Google Scholar
• Kushida K, Takahashi M., Kawana K. Inoue T Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endocrinol Metab 1995; 80: 2447–50
   PubMed Web of Science ®Google Scholar
• Kamel S, Brazier M., Neri V, Picard C, et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Miner Res 1995; 10: 1385–92
   PubMed Web of Science ®Google Scholar
• Arbault P., Grimaux M., Pradet V, Preaudat C, et al. Assessment of urinary pyndinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 1995; 16: 461–7
   PubMed Web of Science ®Google Scholar
• Palmieri G MA. Calcium why and how much?. Miner Electrolyte Metab 1995; 21: 236–41
   Google Scholar
• Steiniche T, Hasling C., Charles P., Eriksen E F, et al. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989; 10: 313–20
   PubMed Web of Science ®Google Scholar
• Lindsay R., Hart D M, Forrest C., Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; ii: 1151–4
   Google Scholar
• Lindsay R, Hart D M, Clark D M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759–63
   PubMed Web of Science ®Google Scholar
• Lindsay R., Hart D M, MacLean A, Clark A C, et al. Bone response to termination of oestrogen treatment. Lancet 1978; i: 1325–7
   Google Scholar
• Felson D T, Zhang Y, Hannan M T., Kiel D P, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6
   PubMed Web of Science ®Google Scholar
• Tohme J, Cosmn F, Lindsay R. Osteoporosis. Principles and Practices of Endocrinology and Metabolism 2nd ed, K L Becker. JB Lippincott. 1995; 567–85
   Google Scholar
• Reginster J Y, Deroisy R, Lecart M P., Sarlet N, et al. A doubleblind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452–8
   PubMed Web of Science ®Google Scholar
• Gennari C., Agnusdei D., Montagnani M., Gonnelli S., Civet-Elli R. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50: 381–3
   Google Scholar
• Azria M. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995; 57: 405–8
   PubMed Web of Science ®Google Scholar
• Chesnut C H, III, McClung Mr, Ensrud K E., Bell N H, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144–52
   PubMed Web of Science ®Google Scholar
• Wimalawansa S J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99: 36–42
   PubMed Web of Science ®Google Scholar
• Goebel J A, Birge S J, Price S C., Hanson J M, et al. Estrogen replacement therapy and postural stability in the elderly. Am J Otol 1995; 16: 470–4
   PubMedGoogle Scholar
• Struys A, Snelder A A, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99: 235–42
   PubMed Web of Science ®Google Scholar
• Filipponi P, Pedetti M, Fedeli L, Cini L, et al. Cyclical clod-ronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995; 10: 697–703
   PubMed Web of Science ®Google Scholar
• Francis R M. Oral bisphosphonates in the treatment of osteoporosis -a review. Curr Ther Res 1995; 56: 831–51
   Web of Science ®Google Scholar
• Chapuy M C., Arlot M E, Duboeuf F, Brun J, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Harris S S, Krall E A, Dallal G E, et al. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 1995; 61: 1140–5
   PubMed Web of Science ®Google Scholar
• Byrne PM., Freaney R, McKenna M J. Vitamin D supplementation in the elderly: review of safety and effectiveness of different regimes. Calcif Tissue Int 1995; 56: 518–20
   Google Scholar
• Hamdy N AT, Kanis J A, Beneton M NC, Brown C B, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–63
   PubMed Web of Science ®Google Scholar
• Reid I R., Arnes R W, Evans M C., Gamble G D, Sharpe S J. Longterm effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98: 331–5
   PubMed Web of Science ®Google Scholar
• Kohrt W M, Birge S J, Jr. Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women. Osteoporosis Int 1995; 5: 150–5
   PubMed Web of Science ®Google Scholar
• Haines C J, Chung T KH, Leung P C., Hsu S YC, Leung D HY. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995; 16: 529–31
   PubMed Web of Science ®Google Scholar
• Takada J., Bay link D J, Lau K-H W. Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells. J Bone Miner Res 1995; 10: 1512–22
   PubMedGoogle Scholar
• Riggs B L, Seeman E, Hodgson S F, Taves D R, O'Fallon W M. Effect of the fluoride-calcium regimen on the vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982; 306: 445–50
   Google Scholar
• Pak C YC, Sakhaee K, Adams-Huet B, Piziak V, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995; 123: 401–8
   PubMed Web of Science ®Google Scholar
• Kauffman R K, Bryant H U. Selective estrogen receptor modulators. DN & P 1995; 8: 531–9
   Google Scholar
• Rymer J, Chapman M, Fogelman I. The effect of tibolone on postmenopausal bone loss. Menopause Digest 1995; 4: 16–7
   Google Scholar
• Poor G, Atkinson E J, Lewallen D G, O'Fallon W M, Melton L J, III. Age-related hip fractures in men: clinical spectrum and shortterm outcomes. Osteoporosis Int 1995; 5: 419–26
   Web of Science ®Google Scholar
• Luisetto G, Mastrogiacomi I, Bonanni G, Pozzan G, et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporosis Int 1995; 5: 455–61
   Google Scholar
• Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol 1995; 14(suppl. 3)32–9
   Google Scholar
• Marel G M. Osteoporosis in men. Curr Ther 1995; 36: 21–7
   Google Scholar
• Orwoll E S, Klein R E. Osteoporosis in men. Endocrine Reviews 1995; 16: 87–116
   PubMed Web of Science ®Google Scholar
• Goldbloom R, Battista R N. The periodic health examination: 1. Introduction. Can Med Assoc J 1988; 138: 617–26
   Google Scholar
• Swedish Council on Technology Assessment in Health Care (SBU). SBU Bone Density Project. Overview & Summary of Previous Reports. SBU, StockholmSweden April, 1994
   Google Scholar
• Office of Technology Assessment. Congress of the United States. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Vol. 1: Cost-Effectiveness Analysis. Washington, DC August, 1995
   Google Scholar
• Kanis J A. The future of HRT and osteoporosis: an epidemiologic perspective. Menopause. European Consensus Development, MontreuxSwitzerland 1996; 269–76
   Google Scholar
• Grady D, Rubin S M, Petitti D B, Fox C S, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37
   PubMed Web of Science ®Google Scholar
• Ettinger B, Grady D. Maximizing the benefit of oestrogen therapy for prevention of osteoporosis. J North Am Menopause Soc 1994; 1: 19–24
   Google Scholar
• Agence Nationale pour le Développement de l'Evaluation Médicale, Evaluation of Bone Mineral Density Measurement. ANDEM, ParisFrance 1991, October
   Google Scholar
• Germany Doubts Value of Osteoporosis Screening. Clinica October, 1994; 7: 626
   Google Scholar
• University of Leeds, School of Public Health, and University of York, Royal College of Physicians. Screening of Osteoporosis to Prevent Fractures. Effective Health Care January, 1992; 1: 1–10
   Google Scholar